The India biologics market is charting an impressive course, projected to reach a staggering USD 166.91 billion by 2035, propelled by a compound annual growth rate (CAGR) of 16.888%. The market, valued at USD 30.81 billion in 2024, is on a trajectory that highlights the country's commitment to advancing affordable healthcare solutions. Innovations in biologics, particularly in monoclonal...